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Abstract
The acute phase protein Pentraxin 3 (PTX3) plays a non-redundant role as a soluble pattern recognition receptor for
selected pathogens and it represents a rapid biomarker for primary local activation of innate immunity and
inflammation. Recent evidence indicates that PTX3 exerts an important role in modulating the cardiovascular
system in humans and experimental models. In particular, there are conflicting points concerning the effects of
PTX3 in cardiovascular diseases (CVD) since several observations indicate a cardiovascular protective effect of PTX3
while others speculate that the increased plasma levels of PTX3 in subjects with CVD correlate with disease severity
and with poor prognosis in elderly patients.
In the present review, we discuss the multifaceted effects of PTX3 on the cardiovascular system focusing on its
involvement in atherosclerosis, endothelial function, hypertension, myocardial infarction and angiogenesis. This may
help to explain how the specific modulation of PTX3 such as the use of different dosing, time, and target organs
could help to contain different vascular diseases. These opposite actions of PTX3 will be emphasized concerning
the modulation of cardiovascular system where potential therapeutic implications of PTX3 in humans are discussed.
Keywords: Pentraxin 3, Acute phase protein of inflammation, Cardiovascular diseases, Myocardial infarction,
Atherosclerosis, Angiogenesis
Abbreviations: AMI, Acute myocardial infarction; ApoE, Apolipoprotein E; CRP, C-reactive protein;
CVD, Cardiovascular diseases; ECM, Extracellular matrix deposition; FGF2, Fibroblast growth factor 2; HF, Heart failure;
IKK, IkB kinase; IL-6, Interleukin-6; LPS, Lipopolysaccharides; MI, Myocardial infarction; MMP, Matrix metalloprotease;
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Background
PTX3 belongs to a superfamily of phylogenically con-
served multimeric proteins, which includes short and
long pentraxins [1, 2]. All these proteins play a critical
role in innate immunity and they are generally consid-
ered acute phase immunity proteins [2, 3]. However,
their effects which are grounded on the modulation of
the cardiovascular system influence a variety of phenom-
ena such as inflammation, angiogenesis, tumorigenesis,
cell adhesion [4, 5]. Short and long pentraxins possess a
different protein size and they are synthesized by
different genes under the influence of different gene pro-
moters. In fact, short and long pentraxins are produced
by different cell types in response to different stimuli
and possess different molecular targets (Fig. 1). Among
short pentraxins C-reactive protein (CRP) is well known.
This protein is produced by hepatocytes and other cell
types during inflammation. Release of CRP is induced by
pro-inflammatory cytokines (mainly interleukin-6, IL-6).
Similarly, a short pentraxin is the serum amyloid P-
component (SAP), which is solely synthesized by hepato-
cytes [6].
In contrast, PTX3 belongs to long pentraxins and, as
mentioned above, it possesses multifaceted properties
extending beyond the fields of immunity and inflamma-
tion to CVD [7, 8].
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Fig. 1 Activity of PTX3 in innate immunity. PTX3 represents the humoral arm of the innate immunity. Inflammatory cytokines, Toll-like receptors (TLRs),
microorganisms and microbial moieties stimulate secretion of PTX3 by polymorphonuclear (PMN) neutrophils, macrophages, and dendritic cells. (1) Release
of PTX3 by PMN neutrophils occurs quickly and casts an immediate defensive response. In fact, these cells possesscytosolic granules containing a stored,
ready- to-release, pool of PTX3. (2) Macrophages and dendritic cells are other effectors of the innate immunity, which neo-synthesize PTX3 upon
stimulation. This newly synthesized pool of PTX3cells is responsible for a slower response to infective agents, which might persist even several days.
Released PTX3 regulates inflammatory reactions by acting through several pathways/mechanisms: I) PTX3 released by PMN neutrophils localizesat level of
neutrophil extracellular traps (NETs). NETs represent an extracellular fibrillary network, where some nuclear components, such as DNA and histones, are
variously assembled with bactericidal proteins, such as azurocidin1(AZU1) andmyeloperoxidase(MPO). Within NETs, PTX3 and anti-microbial molecules
converge and cooperate to enhance binding and killing of infective agents. II) PTX3 released in the extracellular space binds to specific microbial ligands
and activates the complement cascade through interaction with C1q particles (classical pathway) or ficolins and mannose-binding lectins
(lectin-mediated pathway). PTX3-induced complement activation enhances the inflammatory response. III) Finally, extracellular PTX3 opsonizes
microorganisms binding to specific molecules on the cell surface (i.e. zymosan on Aspergillusfumigatus) and, in turn, it is recognized by
Fcgamma receptors expressed by phagocytic cells, thus promoting microbial clearance. The interaction of PTX3with Fcgamma receptors indicates the
antibody-like function of PTX3 and underlies its functional overlapping between innate and adaptive immunity during inflammation. (FcγR Fcgamma
receptor, IL-1 interleukin-1, LPS lipopolysaccaride, PTX3 pentraxin 3, TNF-alpha tumor necrosis factor-alpha)
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Interestingly, its multiple roles can be considered as
site-specific since its production occurs in a variety of
cell types, including endothelial cells, fibroblasts, hepato-
cytes, and monocytes. Moreover, during an acute phase
response induced by LPS, PTX3 is expressed in a variety
of organs, most prominently in the heart and skeletal
muscle, unlike SAP, which is produced only in the liver
[9]. Thus, this specific production pattern of PTX3,
explains its involvement in multiple cardiovascular
disorders.
The present review focuses on findings in humans and
it discusses the molecular mechanisms encompassing
experimental models and human beings.
PTX3 in cardiovascular diseases
Cardiovascular diseases (CVD) represent the major
cause of death in the developed world [10]. In addition
to well established risk factors such as diabetes, hyper-
tension, dyslipidemia, recent evidence indicates that as it
occurs for molecules belonging to the acute phase of in-
flammation, PTX3 may play a key role in the onset and
progression of CVD [11–13].
Thus, PTX3 represents a specific and sensitive marker
connecting inflammation with CVD since it is expressed
and released by most cell compartments involved in the
onset and progression of CVD.
PTX3 is involved in a variety of molecular mechanisms
leading to vascular damage and its elevated plasma levels
represent a significant predictor of frailty in elderly
hypertensive patients [14]. In fact, blood vessels produce
large amounts of PTX3 during inflammation, and the
level of circulating PTX3 increases in several patho-
logical conditions affecting the cardiovascular system
[15, 16].
Here, we highlight the bad or good associations be-
tween PTX3 and CVD in humans. In addition, in experi-
mental models we reported the mechanisms by which
this inflammatory protein may exert itson the cardiovas-
cular actions.
Atherosclerosis
Although cholesterol accumulation intimal layer is the
major pathological feature of atherogenesis, growing
evidence suggests that the inflammatory state repre-
sents the major detrimental factor for the progression
of atherosclerosis both in young and in elderly sub-
jects. In fact, the earliest stage of atherosclerotic dam-
age is characterized by infiltration of macrophages
and T-lymphocytes, which are progressively activated
during the course of the damage [17, 18]. Based on
the kind of cell phenotype being recruited (macro-
phages and vascular cells), which is known to produce
PTX3, this protein was investigated as a potential
modulator of atherosclerosis.
In fact, human sclerotic mammary arteries possess
high levels of PTX3, which is mainly localized within
endothelial cells and macrophages [19, 20]. In addition,
smooth muscle cells, treated with inflammatory stimuli
such as oxidized lipoproteins, increase their PTX3
mRNA level. This effect leads to a vascular acute-phase-
response activating the classic pathway of complement
[21], which represents one of the most important mech-
anisms leading to chemo tactic and pro-inflammatory ef-
fects. The link between PTX3 and complement system
was confirmed by the occurrence of high PTX3 level
within atherosclerosis-related coronary arterial thrombi
that are mainly constituted by resident macrophages,
neutrophils and foam cells [22].
Recently, epidemiological and clinical data candidate
PTX3 as a valid biomarker for atherosclerosis [19, 22].
In particular, PTX3 plays a role in the regulation of in-
nate resistance to inflammatory reactions, it is strongly
expressed in atherosclerotic arteries [23] and its high
plasma levels were found to be related with severity of
coronary atherosclerosis [24]. Accordingly, PTX3 levels
are significantly increased in patients with carotid sten-
osis [25], as well as in patients with acute coronary syn-
drome [26], in whom PTX3 is a candidate biomarker for
plaque vulnerability [27]. Finally, PTX3 has been indi-
cated also as a marker of neo-intimal thickening after
vascular injury, since elevated levels of PTX3 have been
found in patients with atherosclerosis, after 15 min from
coronary stenting [28].
Although the presence of PTX3 in human atheroscler-
otic damage is well defined, its causal role in the onset
and progression of atherosclerosis, remains unclear.
Here, data obtained in experimental models are reviewed
aimed at suggesting the mechanistic role of PTX3 in
atherogenesis.
In particular, it has been reported that PTX3, by inter-
acting with P-selectin, a cell-adhesion molecule involved
in the tethering and rolling of leukocytes and platelets
on activated endothelial cells, attenuates leukocytes re-
cruitment at the site of inflammation [29]. These data
clearly indicate a protective role of PTX3 in atheroscler-
osis. In keeping with this, in a double knockout mouse
model for PTX3 and apolipoprotein E (ApoE), macro-
phages infiltration was enhanced, and a dramatic in-
crease of atherosclerosis was reported. The molecular
analysis indicates a dramatic rise in the pattern of in-
flammatory genes within vascular wall concomitant with
up-regulation of pro-inflammatory mediators such as
chemokines, cytokines, adhesion molecules, E-selectin
and transcription factors, such as NF-kB [30].
In contrast, PTX3 was also reported to induce dele-
terious effects in the pathogenesis of atherothrombosis
[31]. On this regard, it has been demonstrated that
PTX3 increases the tissue factor (TF) expression in
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mononuclear and endothelial cells. The increased level
of TF, the main orchestrator of the coagulation cascade,
causes the thrombus formation, a feature of atheroscler-
osis [32]. PTX3 might also interfere with plaque stability
by binding the fibroblast growth factor 2 (FGF2), that
play a role in proliferation and migration of smooth
muscle cells [33]. This evidence suggests a bad cop for
PTX3, which promotes lesion progression through a
stronger innate immune response. Recently, PTX3 has
been proposed as a potential therapeutic target to limit
the development of atherosclerosis. In fact, by using a
cell model of atherosclerosis, it was shown that suppres-
sion of PTX3 reduces inflammation and apoptosis medi-
ated by the IkB kinase (IKK)/IkB/nuclear factor-kB (NF-
kB) pathway [34].
Actually, the role of PTX3 in the atherosclerosis is
not well-understood. It will be interesting to examine
the role of the protein in complement activation
during atherogenesis to define the specific role of
PTX3 in the atherosclerosis. Overall, PTX3 seems to
exert detrimental effects on atherosclerotic process
since it promotes plagues formation and leads to an
amplification of vascular inflammation such as to be
candidate it as a new possible biomarker for plaque
vulnerability. However, only in those conditions in
which it is able to reduce macrophages infiltration
and the expression of adhesion molecules it exerts
beneficial effects.
Endothelial dysfunction and hypertension
Endothelial dysfunction is a typical trait of several
cardiovascular disorders including arterial hypertension.
The impairment of the nitric oxide pathway and the
enhanced smooth muscle vasoconstriction represent the
main mechanisms leading to endothelial dysfunction in
hypertension [35, 36].
A growing body of evidence attributes to local and
systemic inflammation a key role in the development of
endothelial dysfunction, thus suggesting a key role for
acute phase proteins [37, 38].
On this regard, high plasma levels of the inflammatory
molecule PTX3 were associated with endothelial dys-
function in different human diseases. Patients with
chronic kidney diseases and with preeclampsia, a multi-
systemic disorder associated with hypertension [39–41],
show elevated PTX3 plasma levels which were correlated
with the severity of endothelial dysfunction [39, 40, 42].
In addition, elevated plasma level of PTX3 have been
found in patients with high systolic and diastolic blood
pressure levels [16, 43] and in elderly hypertensive pa-
tients with high 24-h blood pressure levels [14]. In pul-
monary arterial hypertension, PTX3 has been proposed
as a more specific and sensitive biomarker compared
with brain natriuretic peptide, which so far, was
considered the gold standard marker for pulmonary
hypertension [44, 45].
The evidence described so far in humans suggests a
potential role of PTX3 in regulating vascular homeosta-
sis. In experimental models, the absence of PTX3 is
accompanied by massive suppression of tissue inflamma-
tion, cell injury and it determines decreased lethality
after reperfusion of an ischemic superior mesenteric
artery in mice, thus demonstrating that PTX3 is relevant
in conditioning tissue damage [46]. In a recent study by
Carrizzo et al. we investigated the molecular mecha-
nisms recruited by PTX3 to induce damage of mesen-
teric artery. In particular, exogenous administration
of PTX3 in mice impaired endothelial function in
resistance vessels through a P-selectin/matrix metallo-
protease1 pathway, thus producing morphological alter-
ations of endothelial cells and disruption of nitric oxide
signalling. These effects were associated with an increase
in blood pressure in vivo. It is worth to be mentioned
that PTX3, and its mediators of vascular damage are
present at higher levels within plasma of hypertensive
patients compared with normotensive subjects [47].
Based on these data, PTX3 could be considered as a
novel biomarker for hypertension and a new target for
future therapeutic strategy aimed to contain endothelial
dysfunction and associated CVD.
Myocardial infarction
Myocardial infarction (MI) continues to be a significant
cause of mortality and morbidity worldwide [48]. Over
the past 50 years, it has become clear that the cascade of
thrombotic events following atherosclerotic plaque rup-
ture causes occlusion of the coronary artery, interrupting
blood supply and oxygen supply to myocardium, thus
producing infarction. The significance of occurrence of
PTX3 expression in the heart from normal and hyper-
trophy human cardiac cells still needs to be clarified for
its physiological pathological role [49, 50].
In older adults it was reported an association between
PTX3 plasma levels, CVD and all causes of death, inde-
pendently from CVD risk factors [25]. In particular,
plasma level of PTX3 increases in patients with acute
myocardial infarction (AMI) after about 7 h from the
onset of symptoms, with a decrease at baseline levels
after three days [50, 51]. Based on these data, PTX3
seems to be at the same time an early indicator of AMI,
and also a prognostic marker for the outcomes of heart
diseases. PTX3 level also predicts cardiac events in pa-
tients with heart failure (HF), suggesting a stratification
of HF patients based on PTX3 plasma level [52]. This is
fully supported by the identification of coronary circula-
tion as the main source of PTX3 in HF patients with
normal ejection fraction [53]. Moreover, in patients with
MI, ST tract elevation and with chronic HF, PTX3, but
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not other cardiac biomarkers, modulating complement
components, predicted 3 months mortality, after adjust-
ment for major risk factors [12, 28, 54].
Recently, PTX3 was suggested to be a prognostic
marker also in patients with coronary artery diseases
after drug stent implantation, and in patients with an-
gina pectoris [55–57], in whom adverse cardiac events
were related with PTX3 plasma levels [58].
These studies in humans, do not allow to establish
the specific action of PTX3 in the myocardium. Thus,
to better characterize the cardiac action of PTX3,
here we report data obtained in transgenic ptx3 defi-
cient mice. After cardiac ischemia- reperfusion injury,
ptx3 deficient mice develop increased myocardial
damage, characterized by no-reflow area, increased
neutrophil infiltration apoptotic cells and decreased
number of capillaries. In addition, in the myocardium
of these mice the C3 complement component in-
creased focally being related with the area of damaged
myocardium. The evidence that in PTX3-KO mice
the administration of exogenous PTX3 reduces com-
plement C3 deposition rescuing the phenotype, high-
lights the cardio-protective effect of PTX3, through
the modulation of the complement cascade [59].
The discovery of PTX3 in the myocardial tissue and
the characterization of its role lead to propose PTX3 as
an early indicator of myocyte irreversible injury in ische-
mic cardiomyopathy. In addition, considering the local
production and the rapid change in plasma concentration,
PTX3 could be considered a novel potential biomarker of
myocardial infarction.
Angiogenesis
Additional activities of PTX3 other than those related to
innate immunity and inflammation have been described,
such as extracellular matrix deposition (ECM), tissue re-
modeling, and angiogenesis. Several studies demonstrate
that PTX3 is required for the secretion of extracellular
matrix. This is critical for a number of functions such as
maturation of the oophorus follicle, which explains why
in PTX3-deficient mice sterility is observed. This condi-
tion seems to be related to a defective PTX3-dependent
incorporation of the glycosaminoglycan hyaluronic acid
into the matrix of the cumulus oophorus [60]. A similar
molecular composition of the ECM, containing hyaluro-
nan (HA), tumor necrosis factor-stimulated gene-6
(TSG-6), and inter-α-inhibitor (IαI), is observed in
rheumatoid arthritis and other inflammatory infiltrates,
suggesting a role of PTX3 also in these conditions [61].
Interestingly, PTX3 regulates angiogenesis via FGF2,
thus interfering with a variety of conditions, including
ontogenesis, growth, inflammation, tissue repair, athero-
sclerosis, and tumors [62]. The PTX3/FGF2 interaction
prevents angiogenesis. Beyond the anti-angiogenetic
activity, the inhibitory effects of PTX3 on FGF2 possess
a therapeutic rationale in the treatment of re-stenosis,
the progressive occlusion of the coronary artery which
occurs often following angioplastic surgery, due to
anomalous FGF2-dependent proliferation and accumula-
tion of smooth muscle cells on the vessel wall [63]. On
the other hand, angiogenesis involves remodeling of
ECM. In this respect, FGF2 modulates degradation of
the ECM by inducing expression of urokinase-type plas-
minogen activator (uPA) and plasminogen activator in-
hibitor (PAI)-1 on endothelial cell surface, with opposite
effects on matrix metalloprotease (MMP) activity. More-
over, FGF2 regulates expression and distribution of
several integrins and cadherins on the plasma membrane
of endothelial cells, thus promoting cell scattering or
adhesion in different stages of angiogenesis [64]. Finally,
in PTX3 deficient mice models a dramatic reduction of
vascular endothelial growth factor receptor 2 (VEG-
FR2)occurs. This contributes to worsening the outcome
of cerebral ischemia associated with a reduction of
vessels formation [65].
Retinal vasculature
Recently, some studies have investigated on the role of
the PTX3 on the modulation of retinal vasculature [66].
In particular, Moon Woo and colleagues have demon-
strated that human retinal pigment epithelial cells are
the major source of PTX3 following pro-inflammatory
cytokines stimulation and that its release exerts an im-
portant role in retinal injury against inflammation and
infection. Diabetic Retinopathy (DR) represents the well-
known microvascular complication of diabetes [67]. A
recent study has demonstrated that PTX3 levels were
significantly elevated in diabetic patients with DR com-
pared to diabetic patients without DR and normal sub-
jects. This association is correlated with an important
retinal microvascular dysfunction, characterized by capil-
lary leakage or closure, leading to ischemia [67, 68]. This
study suggests that plasma PTX3 may be a better pre-
dictor for DR than CRP in diabetic patients. Moreover,
Noma et al. have highlighted the relationship between
PTX3 and retinal diseases such as age-related macular
degeneration (AMD) and retinal vascular occlusion [69].
On this regards, it has been reported an interaction be-
tween PTX3 and the complement regulator factor H
(CFH), a soluble molecule of the alternative pathway of
the complement system involved in AMD pathogenesis.
The authors hypothesize that aberrant expression of
PTX3 could be associated with pathophysiology of AMD
[69] because there is a loss of control of CFH activity.
PTX3 has been evaluated also in the retinal vein occlu-
sion (RVO), the second most common retinal vascular
disease after diabetic retinopathy. This study demon-
strate that PTX3 could be used as a useful diagnostic
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biomarker since patients with RVO have high plasma
level of PTX3 [70]. Finally, during 2016 Zhou and Hu
suggest that the use of PTX3 could be used as an anti-
angiogenic molecule because PTX3 interacts specifically
with FGF2 factor reducing the proliferative diabetic ret-
inopathy thus ameliorating DR condition [68]. Although
there are not specific evaluation of molecular signaling
recruited by PTX3 in retinal vasculature, it could be rep-
resent another important field in which is possible to act
modulating PTX3 to obtain favorable vascular results.
Genetics and epigenetics
Epigenetic modulation of PTX3 gene in cardiovascular
diseases is increasingly emerging. A candidate modu-
lator of PTX3 is TNFα. In fact, TNFα controls the
expression of PTX3 by human adipose tissue, being
potentially implicated in the development of athero-
sclerosis [71], and administration of antibodies against
TNFα lowers the levels of PTX3 transcripts in Kawa-
saki disease (KD) patients with intravenous immuno-
globulin resistance, thus reducing the risk to develop
coronary artery aneurysms [72].
Another very recent study demonstrated that PTX3
gene is over expressed in the presence of Nogo-B, a
member of the reticulon 4 protein family, which is crit-
ical in vessel regeneration [73, 74]. In rheumatoid
synoviocytes transcription of the PTX3 messenger RNA
(mRNA) was found to be directly promoted by serum
amyloid A [75]. Moreover, plasma analysis and gene ex-
pression profile revealed that PTX3 might be involved in
the remote cardioprotective effects observed in mice
after subcutaneous transplantation of heme oxygenase-
1-overexpressing mouse mesenchymal stem cells [76].
Interestingly, in experimental brain stroke PTX3 is
found locally increased in response to the pro-
inflammatory cytokine interleukin-1 and it contributes
to brain recovery by promoting glial scar formation and
resolution of edema [77]. It is worth to be mentioned
that the epigenetic regulation of long pentraxin 3 was
demonstrated to recruit the PI3K/Akt pathway [78].
Remarkably, it was shown that HDL may increase the
expression of PTX3 via activation of the PI3K/Akt
pathway [79], which discloses a further beneficial effects
of PTX3 under the regulation of HDL.
Conclusion
The multiple effects played by PTX3 are now of growing
interest. Here we try to explain the mechanistic interac-
tions of PTX3 in cardiovascular diseases discussing
recent evidence coming from both cardiovascular and
systemic studies showing the fine tuning of time, space,
and organ context, which determine the final outcome
Fig. 2 Schematic representation of the detrimental or beneficial effect of PTX3 in cardiovascular diseases. Red arrow indicates a deleterious effect
evoked by PTX3, in contrast to the Green arrow, which indicates the beneficial effect of the protein. The mechanisms through which the PTX3
exerts its cardiovascular effects are described on the side of the arrows
Fornai et al. Immunity & Ageing  (2016) 13:25 Page 6 of 9
of PTX3 effects including either detrimental or bene-
ficial effects (Fig. 2). Several studies have suggested
PTX3 as a therapeutic tool for cardiovascular disor-
ders although contradictory findings leave this point
unresolved.
Nevertheless, considering that the ptx3-deficient mice
have greater myocardial lesions following the coronary
artery ligation/reperfusion damage due to activation of
C1q [59], the PTX3 stimulation could be used as thera-
peutic tool to reduced AMI damage. Moreover, since
HDL induces PTX3 through PI3K/Akt axis [80] exerting
an atheroprotective effect, the positive modulation of
PTX3 could counterbalancing the over activation of a
proinflammatory atherogenic cascade thus protecting
the vascular wall. Again, based on the interaction be-
tween PTX3 and complement factor H that contribute
to maintain the retinal immunohomeostasis [81], the
stimulation of PTX3 could reduce the pathophysiology
of macular degeneration. Finally, in keeping with the
detrimental vascular effects of PTX3 on endothelium,
mediated by the activation of P-Selectin/MMP1, we wish
to emphasize that PTX3 may represent a novel target to
be blocked to protect blood vessels. Based on these data,
we feel that the balance between the good and the bad
cops of PTX3 must be kept in mind both kind of effects
when planning further developments in human patients.
In particular, the vascular-based therapeutic approach
should be limited to block the vascular effects of PTX3
without affecting its beneficial effects in other organs.
Alternatively one might theoretically plan to combine
opposite actions in different systems. Opposite manipu-
lations of PTX3 for future therapeutic strategies should
be planned to block selectively PTX3-induced molecular
cascade in blood vessel, while concomitantly increasing
its effects in other selective district. These issues
represent a challenge for future PTX3-based drug
development.
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